Rani Therapeutics Holdings Inc (RANI) - Net Assets
Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) has net assets worth $-11.97 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.14 Million) and total liabilities ($22.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RANI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.97 Million |
| % of Total Assets | -118.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19.3 |
Rani Therapeutics Holdings Inc - Net Assets Trend (2019–2024)
This chart illustrates how Rani Therapeutics Holdings Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Rani Therapeutics Holdings Inc for the complete picture of this company's asset base.
Annual Net Assets for Rani Therapeutics Holdings Inc (2019–2024)
The table below shows the annual net assets of Rani Therapeutics Holdings Inc from 2019 to 2024. For live valuation and market cap data, see market cap of Rani Therapeutics Holdings Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.49 Million | -86.27% |
| 2023-12-31 | $25.44 Million | -65.62% |
| 2022-12-31 | $74.00 Million | -39.12% |
| 2021-12-31 | $121.57 Million | +207.26% |
| 2020-12-31 | $-113.34 Million | -17.28% |
| 2019-12-31 | $-96.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rani Therapeutics Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 560700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.25% |
| Other Comprehensive Income | $5.00K | 0.25% |
| Other Components | $104.89 Million | 5265.51% |
| Total Equity | $1.99 Million | 100.00% |
Rani Therapeutics Holdings Inc Competitors by Market Cap
The table below lists competitors of Rani Therapeutics Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Galleon Gold Corp
V:GGO
|
$91.71 Million |
|
Jinro Distillers Co. Ltd
KQ:018120
|
$91.71 Million |
|
Chips&Media Inc
KQ:094360
|
$91.77 Million |
|
CANBRIDGE PHARM.DL-00001
F:MF1
|
$91.77 Million |
|
Aniplus Inc
KQ:310200
|
$91.63 Million |
|
Lakeshore Acquisition III Corp. Ordinary Shares
NASDAQ:LCCC
|
$91.63 Million |
|
Apontis Pharma AG
XETRA:APPH
|
$91.63 Million |
|
Summit State Bank
NASDAQ:SSBI
|
$91.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rani Therapeutics Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,866,000 to 1,992,000, a change of -10,874,000 (-84.5%).
- Net loss of 30,018,000 reduced equity.
- Share repurchases of 304,000 reduced equity.
- New share issuances of 18,262,000 increased equity.
- Other comprehensive income increased equity by 17,000.
- Other factors increased equity by 1,169,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.02 Million | -1506.93% |
| Share Repurchases | $304.00K | -15.26% |
| Share Issuances | $18.26 Million | +916.77% |
| Other Comprehensive Income | $17.00K | +0.85% |
| Other Changes | $1.17 Million | +58.68% |
| Total Change | $- | -84.52% |
Book Value vs Market Value Analysis
This analysis compares Rani Therapeutics Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-5.16 | $0.94 | x |
| 2020-12-31 | $-6.05 | $0.94 | x |
| 2021-12-31 | $2.43 | $0.94 | x |
| 2022-12-31 | $1.55 | $0.94 | x |
| 2023-12-31 | $0.50 | $0.94 | x |
| 2024-12-31 | $0.07 | $0.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rani Therapeutics Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1506.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2920.04%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 18.39x
- Recent ROE (-1506.93%) is below the historical average (-311.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -2716.75% | 0.04x | 0.00x | $-16.93 Million |
| 2020 | 0.00% | -3615.37% | 0.01x | 0.00x | $-5.37 Million |
| 2021 | -17.57% | -306.62% | 0.02x | 2.62x | $-13.07 Million |
| 2022 | -83.00% | 0.00% | 0.00x | 2.93x | $-34.27 Million |
| 2023 | -264.03% | 0.00% | 0.00x | 4.50x | $-35.26 Million |
| 2024 | -1506.93% | -2920.04% | 0.03x | 18.39x | $-30.22 Million |
Industry Comparison
This section compares Rani Therapeutics Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rani Therapeutics Holdings Inc (RANI) | $-11.97 Million | 0.00% | N/A | $91.70 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more